<SEC-DOCUMENT>0001193125-18-058967.txt : 20180227
<SEC-HEADER>0001193125-18-058967.hdr.sgml : 20180227
<ACCEPTANCE-DATETIME>20180226205036
ACCESSION NUMBER:		0001193125-18-058967
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180226
FILED AS OF DATE:		20180227
DATE AS OF CHANGE:		20180226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DBV Technologies S.A.
		CENTRAL INDEX KEY:			0001613780
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36697
		FILM NUMBER:		18642620

	BUSINESS ADDRESS:	
		STREET 1:		177-181 AVENUE PIERRE BROSSOLETTE
		CITY:			MONTROUGE
		STATE:			I0
		ZIP:			92120
		BUSINESS PHONE:		33(0)155427878

	MAIL ADDRESS:	
		STREET 1:		177-181 AVENUE PIERRE BROSSOLETTE
		CITY:			MONTROUGE
		STATE:			I0
		ZIP:			92120
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d539902d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES SECURITIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">6-K</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR <FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Month of February 2018 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-36697</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>DBV TECHNOLOGIES S.A. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">177-181</FONT> avenue Pierre Brossolette </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>92120 Montrouge France </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files
or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F:</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9746;&nbsp;&nbsp;Form
<FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744;&nbsp;&nbsp;Form</FONT> <FONT STYLE="white-space:nowrap">40-F</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated February&nbsp;26, 2018.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>DBV TECHNOLOGIES S.A.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Date: February&nbsp;26, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ David Schilansky</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Schilansky</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deputy Chief Executive Officer</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g539902g74p14.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Press Release </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Montrouge, France, February&nbsp;26, 2018 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><B>DBV
Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Positive preliminary results support Viaskin Milk&#146;s
potential as the first treatment for patients suffering from IgE-mediated cow&#146;s milk protein allergy (CMPA), an unmet medical need for which there are no approved therapies </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">A statistically significant desensitization to milk was observed in children ages two to 11 treated with Viaskin Milk 300 &micro;g for 12 months </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Company evaluating optimal dosing/patient population for future studies </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DBV Technologies (Euronext: DBV &#150; ISIN: FR0010417345 &#150; Nasdaq Stock Market: DBVT) today announced preliminary results from Part B, or Phase II, of a
Phase I/II study evaluating the efficacy and safety of three dose regimens of Viaskin Milk (150 &micro;g, 300 &micro;g, 500 &micro;g) in 198 patients for the treatment of IgE-mediated cow&#146;s milk protein allergy (CMPA). The MILES (Milk Efficacy
and Safety) study was designed to determine a safe and effective dose in two age groups: children ages two to 11 and adolescents ages 12 to 17. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following
analyses of the data, the 300 &micro;g dose was identified as the most effective tested dose for children <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(intent-to-treat</FONT></FONT> (ITT), p=0.042). The Company believes these
preliminary results support further advancement of the Viaskin Milk program, and intends to discuss findings with health authorities in key markets worldwide to determine the design of future studies. Viaskin Milk was granted U.S. Food and Drug
Administration (FDA) Fast Track Designation in September 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>&#147;This is an important milestone for the millions of patients suffering from CMPA
worldwide. We know that small amounts of cow&#146;s milk protein can cause life-threatening reactions, and that this disease has a profoundly negative impact on the quality of life of patients and their caregivers,&#148; </I>said
<B>Dr.</B><B></B><B>&nbsp;Stephen</B><B></B><B>&nbsp;A. Tilles,</B> Executive Director, ASTHMA Inc. Clinical Research Center, Physician Partner at Northwest Allergy&nbsp;&amp; Asthma Center (NAAC), and the Principal Investigator of the MILES
trial.<I> &#147;There are no other treatments in development today for this <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">hard-to-treat</FONT></FONT> disease, and it is exciting to see these encouraging efficacy and safety
results with a novel potential treatment option that appears to be well-tolerated.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary efficacy endpoint of the study evaluated the
percentage of patients who responded to treatment as assessed by <FONT STYLE="white-space:nowrap">pre-specified</FONT> changes from baseline in double-blind-placebo-controlled </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g539902g80j31.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">food challenge (DBPCFC) cumulative reactive doses after 12 months of
treatment<SUP STYLE="font-size:85%; vertical-align:top">1</SUP>. Key secondary endpoints evaluated mean and median cumulative reactive dose (CRD) during the <FONT STYLE="white-space:nowrap">month-12</FONT> DBPCFC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The overall patient population treated according to the protocol <FONT STYLE="white-space:nowrap">(per-protocol</FONT> analysis population) was also
scientifically relevant for this dose-finding study, and the response rate in the 300 &micro;g dose showed a significant improvement versus placebo (p=0.027), which was consistent with ITT statistical trends. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Highlights of the MILES Study </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9726;</TD>
<TD ALIGN="left" VALIGN="top">Analysis of the data showed a statistically significant response in the 300 &micro;g arm in the <FONT STYLE="white-space:nowrap">2-11</FONT> age group (ITT, p=0.042), which was identified as the prioritized population
for future studies. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9726;</TD>
<TD ALIGN="left" VALIGN="top">A significant increase in CRD versus baseline as measured by changes in the <FONT STYLE="white-space:nowrap">month-12</FONT> DBPCFC was observed in children treated with the 300 &micro;g dose as compared to placebo
(ITT, p=0.045). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9726;</TD>
<TD ALIGN="left" VALIGN="top">Viaskin Milk was reported to be well tolerated across all doses with no treatment-related serious adverse events (SAEs). The most commonly reported adverse events were mild and moderate application site reactions.
Overall, the discontinuation rate was 4.5%, with a 1.5% dropout rate due to adverse events. Treatment adherence, as measured by mean patient compliance, was over 95% in all study groups. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of Response Rate and Cumulative Reactive Dose (CRD), ITT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Placebo</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Viaskin<BR>Milk<BR>150 &micro;g</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Viaskin<BR>Milk<BR>300 &micro;g</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Viaskin<BR>Milk<BR>500 &micro;g</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Overall</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>n=53</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>n=49</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>n=49</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>n=47</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Responder Rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mean Change in CRD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">555.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">745.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1201.0</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">723.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Children</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>n=40</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>n=38</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>n=38</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>n=36</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Responder Rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57.9</TD>
<TD NOWRAP VALIGN="bottom">%**&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mean Change in CRD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">565.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">624.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1322.4</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">839.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Adolescents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>n=13</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>n=11</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>n=11</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>n=11</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Responder Rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mean Change in CRD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">525.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1150.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">715.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">364.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">*Geometric Mean <FONT STYLE="white-space:nowrap">P-values</FONT> for CRD, Overall: 0.008, Children: 0.045, **p=0.042 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr.</B><B></B><B>&nbsp;Hugh Sampson</B>, Chief Scientific Officer of DBV Technologies and Kurt Hirschhorn Professor of Pediatrics at the Icahn School of
Medicine at Mount Sinai said,<I> &#147;We would like to thank all of the patients, caregivers and investigators who participated in this trial with Viaskin Milk, our second </I> </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>Defined as patients with either 1) a cow&#146;s milk protein
CRD equal to or greater than 1,444 mg (approximately 45 mL of milk) or 2) a <FONT STYLE="white-space:nowrap">10-fold</FONT> or greater increase in CRD compared to baseline and reaching at least 144 mg cow&#146;s milk protein (approximately 4.5 mL of
milk). </P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g539902g80j31.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Viaskin platform product candidate in food allergies. These studies brought new insight into our understanding of
Viaskin Milk&#146;s unique immunotherapeutic properties and mechanism of action. We will continue working to better understand the appropriate dose regimens and optimal application protocols.&#148;</I> <B>Dr Sampson</B> continued, <I>&#147;We look
forward to discussing next steps with health authorities to move this important program forward, and to most importantly, bringing a potential treatment option to this underserved patient population.&#148;</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Overall, 98.9% of patients completing <FONT STYLE="white-space:nowrap">month-12</FONT> of MILES opted to enroll in the open-label portion of the study and are
currently being treated with Viaskin Milk 500 &micro;g for up to 48 months. The Company will assess next steps on any potential protocol changes with regulatory authorities. Additional results from MILES are expected to be presented at upcoming
medical meetings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the MILES Study </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Viaskin
Milk Efficacy and Safety (MILES) trial is a multi-center, double-blind, placebo-controlled, randomized Phase I/II trial to study the safety and efficacy of Viaskin Milk conducted at 17 sites in North America. The study was divided into two
consecutive parts. Part A of the MILES trial was completed with no safety concerns. Part B was designed to determine a safe and effective dose in two age groups: children ages two to 11 and adolescents ages 12 to 17 with IgE-mediated cow&#146;s milk
protein allergy, or CMPA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">198 patients (18 patients from Part A and 180 patients from Part B) were randomized 1:1:1:1 into four treatment arms to
evaluate three doses of Viaskin Milk, 150 &micro;g, 300 &micro;g and 500 &micro;g, compared to placebo. Each patient underwent a DBPCFC at screening and after 12 months of treatment. The challenge was halted once the patient exhibited an objective
allergic symptom. Patients in MILES received a daily application of the Viaskin Milk patch over 12 months. Each patch was applied for 24 hours on the back of children (age <FONT STYLE="white-space:nowrap">2-11)</FONT> or on the upper arm for
adolescents (age <FONT STYLE="white-space:nowrap">12-17).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary efficacy endpoint was the percentage of treatment responders for each active
treatment group compared to placebo. Responders at <FONT STYLE="white-space:nowrap">month-12</FONT> were defined as patients with either 1) a cow&#146;s milk protein CRD equal to or greater than 1,444 mg (approximately 45 mL of milk) or 2) a <FONT
STYLE="white-space:nowrap">10-fold</FONT> or greater increase in CRD compared to baseline and at least 144 mg cow&#146;s milk protein (approximately 4.5 mL of milk). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following <FONT STYLE="white-space:nowrap">month-12</FONT> all subjects were eligible to switch to the highest dose of Viaskin Milk, 500 &micro;g, and to
continue treatment in an open-label manner for up to a maximum of three additional years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About DBV Technologies</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DBV Technologies is developing Viaskin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, a proprietary technology platform with broad potential
applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, DBV&#146;s method of delivering biologically active compounds to the immune system through intact skin.
With this new class of self-administered and <FONT STYLE="white-space:nowrap">non-invasive</FONT> product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments.
DBV&#146;s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other
immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq
Global Select Market in the form of American Depositary Shares (each representing <FONT STYLE="white-space:nowrap">one-half</FONT> of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: <U><FONT
STYLE="white-space:nowrap">www.dbv-technologies.com</FONT></U> </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g539902g80j31.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release may contain forward-looking statements and estimates, including statements regarding the potential of Viaskin Milk and of the Company&#146;s
and clinical development and regulatory plans regarding Viaskin Milk. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, the products of the Company have not
been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and
related regulatory reviews and approvals, the risk that results of historical clinical trials will not be replicated in future clinical trials and the risk that historical clinical results in one patient population may not be predictive of future
clinical trial results in different patient populations. A further list and description of these risks, uncertainties and other risks can be found in the Company&#146;s regulatory filings with the French Autorit&eacute; des March&eacute;s
Financiers, the Company&#146;s Securities and Exchange Commission filings and reports, including in the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2016 and future filings
and reports by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV
Technologies undertakes no obligation to update or revise the information contained in this Press Release. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DBV Investor Relations Contact </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sara Blum Sherman </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Director, Investor
Relations&nbsp;&amp; Strategy </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1&nbsp;212-271-0740</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">sara.sherman@dbv-technologies.com</FONT> </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DBV Media Contact </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Roberta Di Giorgio </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Director, Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1&nbsp;917-612-2861</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">roberta.digiorgio@dbv-technologies.com</FONT> </U></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g539902g74p14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g539902g74p14.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ +Y BPRU[9XH;<('!Y]Z %V[E+DX- Q HD)W=J %QO(!P.*
M&XV_N\<9ZT[ !PGRC)H$*5$73O2  NPAAUS0,7:-OF9R?:@ VB0DG@@^E "#
M]YUXQ0@#(<;#T!H #\N4' ]: $;]W]WTH 4KY>"#GB@ V[!O!YH -H92Q.#Z
M>E @ \SJ<8H %^<@,< #\Z!B=_+SQGK0 'Y/D4_*?TH 7'EG"G.10 $!,%3D
MT"#'R;]WS4  7S"S$XQ0,%4RGYB>/2F"0 ;CL/04@#&T[.W\J !AY>=I[>E
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MO<8H& ;C;V% @QY6&P#F@8FT*-^ >^* %VAOGP.* #'F'H!@4 ! <A< 8[T
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MG?UH " B[6&2<8- "<1\$#F@!V A!89'I0 8X#=O[M !C<&(X&>E,!,>9C
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M_P!7@=>M !]TE, YH 7:L78'(H 3 3#<4 !4%2_'% "[?,R>!B@!!B7C &*
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M$H&Q]: #KC8#[T (<;0,'/?F@!<[\!^%_G0 F20%)PGKB@!22N54_+G&<=*
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MI0 H_<\@ \4 -!*#=U]J %R6^8]NU  291R ,#O0 9\S (Q]: #)("8'3&:
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M71:GTFRL+V2VN=0(=6*@I#N5>>,G/'&.F<5*J2DKI#=.,7:Y']DN;.VU*-Y
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M!CB@ SSU^3- "L1N(4_+QDT #8'W#GUYH 4D8 0<T!<3($9P.<TP%X&X/UI
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M@B@ 4%LEFP?2@ 7+X#&F(.6;:6.*0P(Q\JMQ_*@ ;,8PK'F@0KC9RK<^_>F
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MMVH 4?-DDX- "(2YPQQB@ SVR< ]: #'E@,>1Z4 (%V@/QZXH =C<-_ ]!0
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M8S^[_6@ ^YD8!R: #F+K@YH ,&/#$Y_I0 ;3][].U  5,A)Z8H ,>9TXQ[4
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MG[O]:  _)E2 <F@ VF/J0<B@  * -U]C0 %<J7_'% "[2_(.* $&9>GRX]*
M '^' XH ""G+Y*GU- "8PNXYV^F: '%><@G;Z4 )@N?DR,>E !C) 7@XZT
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MH 7!!!)^7TH 3!*$C[OIF@!?O'*<#TH 0?,%"#''6@ '. /O4 !^4%2,MZT
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MQ[!]CM?^?:+_ +X%'/+N'LX]A/L=M_S[1?\ ? _PHYY=P]G'L'V.V_Y]HO\
MO@?X4<\NX>SCV%^QVO\ S[1?]\"CGEW#V<>P?8[4<?9HO^^!1SR[A[./8/L=
MM_S[1?\ ? HYY=P]G'L'V.U_Y]HO^^!1SR[A[./8/L=M_P ^\7_? HYY=P]G
M'L'V.VSG[-%_WP*.>7</9Q[!]CM?^?:+_O@4<\NX>SCV#[';?\^\7_? HYY=
MP]G'L'V.U_Y]HO\ O@4<\NX>SCV#[':_\^T7_? HYY=P]G'L'V.U_P"?:+_O
M@4<\NX>SCV#[':_\^T7_ 'P*.>7</9Q[!]CM?^?:+_O@4<\NX>SCV#[':_\
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M!1CCK7L'DB%BP\O'/3K0 H;:-I&3]: #/EG#"@ ^X0Q&<CCF@#5\.:>FI:Y
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % 'AY(.W9UKVSQA"5V@#[U "C 7YOO4  (!._\ 6@ ! 8%NF.* -;PW
M>II^NPS2G;;MF-CV (Z_G65:-X-(TIRY97(-8TF?2;]X7C81YRCCHR^U$*D9
M:BG!QT+OAK3'OM7MYE4K;02!G<C R",#ZGI4UIQ47W+I0;EKL/U':?&V /F^
MUI_,4H?P4$OXC+?C+2G6_EOXDWPR8#E>=C  8/Z5&'FN7E95:#<KHP-/T^?4
M+H6T$1>1CR<< >I/:MW4C'J8J,I&GXHN(#J$%G"=T5G"L()Z$CK_ $K*A%I7
M?4UK--V1+X9VW]O>:).0$N%\R$G^%Q_];'Y45_=:FN@4M5R/J1>*;J-KV/3[
M8?Z-8H(P!T+=S_3\***:5WU%5:;LMD8+8(.P=!728BG#?<!!]1Q0 W *X (;
MUH 7HNUOO^M "J #\P^E-"8G<!P0,=Z!@!A@3]S-  V"<J#M[XI #8) CX]>
M*5QV#(. HP13$'&W!'S_ $YI@ *KNW_>S2 %POWQ].* .GT'P;/J(%Q?%X+7
M^%"/G;WYZ"N.IB.7X3KIX?F^([^RT^UTZ$0VD"Q)Z =?J>]<4I2ENSKC",=D
M6JDL* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % 'B# Q ,*]L\:S$(V1[\C/6BX6%QN4MQ1<+
MO[PDG'%%Q:FM;QQWFG:=:,J)ONI%,@SD<1].<=_TK':4GZ&O1"30V;P3QQ^4
MKQ<J8A(S=0/FW#'?J,<XHB]1R5D1W2V]E</9"T\T  >9N(=C_>';'X'BG>^K
M)L6F^RB72[=[?S&GB1&?<05!8@8Q_7-+75W+OL5WCM+&RM7>W\^63=OW,0
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >'_ .K(9N<#
MCFO;1X]W</NC<1Q]:+"N+U&X=.M%@N)RYXX HL@'EW=4B#$(A+ 9Z'C)^O _
M*E9!=[$LU]=7*"":=W&<D%N"?7WHY4AW8?;KI(?(^T2;"-H&X]/2BR"[(_.F
MC=',C9C&$.?NXZ8]*+(5V(TDI5?,8LHZ G.,]:=D%V2I>7<<LLR7#@R$L_S'
MYCZGU-+E2Z#YGW&/-/,TA:5SO/SY8_,1Z^M%DN@78^2^N[J/RVGD9!C(+GGT
MSZU-D.[+D&L>7%&B1S!H\803D1Y'<K_3.*7*.[*"W5PK(1*PD3[I#'C/7^?Z
MU=D3=H>U]="19'GD+H"%.[IGKBBR"[(Y999)3+.S.QZDG/TIV0KD8^4 G(7T
MS0 ;2PW+TH -OF?=&,>] !]X  '([T & <(!@YZTP#(4E3CGI[T *?W9R>G:
MD&Q9T_3KG4+Q+>VCWLQ_!1ZD]A4RG&*NRHP<M$CT_0]!MM$M]L?SSM_K)".6
M_P !7EU*KFST:5)4T:]9&P4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 >'\J1Y@.,5[:/&$Y &<[* %[$C.WO0 N"3^[!''- "?W=N00.M !@>^
M_/K0 9 SN!+=J #E?]8"?2@ '\);..W/2@!<''&=M !AB3LSCO0 8Q_J\^]
M"+T!7[W>@   !!SNH #QG?DG% !SN ?.* #'3<3LH /FQA.$H 4 D@Q@]*8M
M1/\ <SD#F@ P,# ._- T'7ANM S0TC1[K6+KR8D. ,M(?NH/?W]JRJ58PW+C
M3E/8].T?1K;1K3R+?+$\O(WWF->7.;F[GI1@H[&E6984P"@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MY]3ZFO/E)R=V=T8J*T+%2,6D,*8!0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % 'B$P 1<#%>V>*(P @8XYH&+@;2<<\?RH
M (P.>* !?O?A0 @^]CMF@!'[_6@!T@ Q@4 !Z)]?Z4 )_P LQ]: '(!SQWH
M:O>@!$^\1Z,: #NWX4#D#_TH <X (P.QIB$/$>?>@!1]UOI4@" $'(!XJY;#
M@KGL&D010:9;K#$D8* D(H&3ZUXM1MRU/4II):%ZI+84ABT )0(6A#$H * "
M@ H * "@ H$% Q:$ AH$PH&% !0 4  H$@H * %H0Q* "@ H * "@ H *!!0
M,6A (:!,*!A0 4 %  *!(* "@!:$,2@ H * "@ H * "@04#%H0"&@3"@84
M% !0 "@2"@ H 6A#$H * "@ H * "@ H$% Q:$ AH$PH&% !0 4  H$@H *
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g539902g80j31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g539902g80j31.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M4 &24V8'IFBP "%!7 ^M%@$'[LY(ZT *!M.[KGM0 'KOZ#/3-  3O.<8]J
M_-P,# HL 9W*% Q[T6 09 V8'IUH 49C&#S0 BCRSG@Y_2@  *D.<=>F: #E
MOF&!CM0 $;U],"@!3^\ '3O0 $Y&WC\Z  '9\O!'KF@ !V$]#0 #Y#NZY[4
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M #H 1?D^\*   J<D?+VH ,=P/E!H 4_-DH#TH #AN%'_ -:@!"05V@?-_*@
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MS0 $  !#\U "':$!&=U "@ C+=1[T (,,QW9'''- "\=&)V]N: $P,X.=E
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MUH " I'EGMR* %^48*_>- "#:$SGYO2@!0 0=YY[9H 0<\.?I0 <' /W1TH
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M*/K, ^K3$'@35U.0]OG_ 'S_ (4_K, ^K3 >!-7!SOM]WKO/^%'UF ?5I@?
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M_4GFN&524GJ=D:<8[%X5!H% !0 4 % "T % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M$RJ3GELCBK)#.XC?\H[4AB9Z*<A?I0 N2 5'(Z9H 7.P_+R* $!VC*DD]Q0
M9 (()+>F* $Z@D]: %SN^]Q0  [L!\@>IH ,X&TY"^N* %R1D#.* $!*_<Y)
MZ\=* +%E97%_<+#9QM+.W) XQ[D]J4YJ"NRXP<]$>BZ!X4M])VW,^)[PC[Q^
MZA_V?\?Y5YM6NYZ+8]"E24%KN='7.;!0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M>V,5LGS-R\AY9S[_ .%>7.;F[L]&$%!61HU!H% !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@#PX;=@Q]XXKVCQ@X\ML_>[_6F
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#P_&U X)SQ^-
M>T>, !*E\G/IZ4P!<NN2?>@ 'S':3TH ,'(7) SC-  V5(4'CU]*8"LI097)
M'?VI#-*"\M6L([6^25UC8F*2(@,N>H(/!&:Q<6I7B7S)Z,==W]NVDBQMX'A5
M)O,W.V68X(.?THY)7O?H/GLK)=2Q=:AI>JWTMU=6MPDA;Y1"X^;TSD=>W%)0
MG!63!SB]6C.O+UK^Z$A3RDC54BC4Y"*.@K1125B'-MW'ZGJ<VJ74<DJ[%1-@
MVC@MU8_4DDU-.'+=(<I<Q0R=Q7/RYZUJ0*?E.U2?>@!#\F,-^E  1A0P)R:
M#DJ6SS0 *"_5N>U  HWG!/2@ Y)"9XZ4 !RIP&."1^% "OE!\I.>XI7%8ZKP
MYX2:_"7E[O2V/S*O0R#^@KEK5^7W8G51HWUEL>AQQI#&L<:A$4850, "O/;N
M=Z5E9#J!A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MTE1(T0)M)Z #&>15(3*X_=Y'6J(%(\ML]: $Q@!^/I0 #D;^.G2@!<>8,]*
M$ WX' P* #K\G3!ZT 2VUK/=3BVMH6ED8\!1G\?_ *]$I**NQ).3LCOO#_@V
M*P*W-\5FN!RL?5$_Q/Z5Y]:NY:1V.^E04?>>YUF*Y#JL+0,* "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M9^\W5F^I[UPRFY/4[8P4=B]4EA0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % 'AJDDA2>*]H\84@J^P$[>F*8 W[LX7@4 *X\O!4X
M[4 !_P!6'_B]:  #<'8]5Z4 "C>N6.<=* $0EVP3P* $R0VS/% #C\K8!P*
M$D)C;Y3VH 5OE17'!/6@ _@W_P 5 "*-PW$G-  K%S@],9JA"*2<*>E);C>P
MK$J^P?=R!BFR4=5X5\/V>IQO-<&7$;XV*P"GCOQG]:XZ]24-CII04GJ=W8Z9
M9:<FVTMHXN "5')'N>IK@E)RW.^,5'8N5)84 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
<0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
